First clinical study with CS1 completed
Cereno Scientific today announces that the company has completed its clinical study with drug candidate CS1. Preliminary analysis of the study data shows that CS1 was safe and well tolerated.The study was performed in collaboration with Cereno Scientific’s clinical research partner, CTC in Uppsala. In the study, individuals with an increased risk profile for thrombosis participated in evaluating safety, tolerability and pharmacokinetic properties of CS1. Furthermore, effects on risk markers for thrombosis were studied.Cereno continues to analyse all data from the study and hopes to be